BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 19395463)

  • 21. Risk stratification after radical prostatectomy in men with pathologically organ-confined prostate cancer using volume-weighted mean nuclear volume.
    Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
    Prostate; 2005 Aug; 64(3):217-23. PubMed ID: 15712275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer.
    Dvorak T; Chen MH; Renshaw AA; Loffredo M; Richie JP; D'Amico AV
    Urology; 2005 Nov; 66(5):1024-8. PubMed ID: 16286117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
    Jones TD; Koch MO; Bunde PJ; Cheng L
    BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antegrade radical retropubic prostatectomy with preliminary ligation of vascular pedicles in 614 consecutive patients.
    Kawakami S; Fukui I; Yonese J; Okubo Y; Yamamoto S; Tsukamoto T; Ishikawa Y
    Jpn J Clin Oncol; 2007 Jul; 37(7):528-33. PubMed ID: 17720739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
    Weight CJ; Reuther AM; Gunn PW; Zippe CR; Dhar NB; Klein EA
    Urology; 2008 Jan; 71(1):141-5. PubMed ID: 18242383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuing trends in pathological stage migration in radical prostatectomy specimens.
    Derweesh IH; Kupelian PA; Zippe C; Levin HS; Brainard J; Magi-Galluzzi C; Myles J; Reuther AM; Klein EA
    Urol Oncol; 2004; 22(4):300-6. PubMed ID: 15283887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy.
    Hayashi N; Urashima M; Kuruma H; Arai Y; Kuwao S; Iwamura M; Egawa S
    BJU Int; 2008 Jan; 101(2):175-80. PubMed ID: 17850362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer.
    Carini M; Masieri L; Minervini A; Lapini A; Serni S
    Eur Urol; 2008 Mar; 53(3):554-61. PubMed ID: 17683854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy.
    Zwergel U; Suttmann H; Schroeder T; Siemer S; Wullich B; Kamradt J; Lehmann J; Stoeckle M
    Eur Urol; 2007 Oct; 52(4):1058-65. PubMed ID: 17418938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical prostatectomy: survival outcome and correlation to prostate-specific antigen levels.
    Oberpenning F; Hamm M; Schmid HP; Hertle L; Semjonow A
    Anticancer Res; 2000; 20(6D):4969-72. PubMed ID: 11326649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
    Xylinas E; Drouin SJ; Comperat E; Vaessen C; Renard-Penna R; Misrai V; Bitker MO; Chartier-Kastler E; Richard F; Cussenot O; Roupret M
    BJU Int; 2009 May; 103(9):1173-8; discussion 1178. PubMed ID: 19040530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer.
    Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Tilley WD; Skinner JM; Horsfall DJ
    Clin Cancer Res; 1997 Jun; 3(6):983-92. PubMed ID: 9815775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
    Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
    Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.
    Desireddi NV; Roehl KA; Loeb S; Yu X; Griffin CR; Kundu SK; Han M; Catalona WJ
    Urology; 2007 Nov; 70(5):950-5. PubMed ID: 18068453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.